Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Zongertinib Research Could Represent Next Wave in HER2-Mutated NSCLC Management

November 6th 2024

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.

Notable 2024/Early 2025 Multiple Myeloma NCCN Guideline Updates Feature Quadruplets and More

November 6th 2024

Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.

Dr Lotan on Ongoing Research With Novel Agents in BCG-Unresponsive NMIBC

November 5th 2024

Yair Lotan, MD, discusses ongoing research with novel agents in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Westbrook on the Potential Use of ccRCC Therapies in Non-ccRCC

November 5th 2024

Thomas Westbrook, MD, discusses the investigation of approved ccRCC treatments in patients with non-ccRCC.

How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd

November 4th 2024

Dr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.

Continued Development of RAS Inhibitors Leads the Charge in Pancreatic Cancer Research

November 4th 2024

Tanios S. Bekaii-Saab, MD, discusses the evolving role of RAS-targeted therapies in pancreatic cancer and where future research in the field may be headed.

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL

November 4th 2024

Treatment with the third-generation anti-CD19 CAR T-cell therapy HD-CAR-1 is feasible and safe in heavily pretreated chronic lymphocytic leukemia.

BXQ-350 Is Well Tolerated, Shows Clinical Activity in Advanced Solid Tumors

November 4th 2024

BXQ-350 was well tolerated and generated clinical activity in patients with advanced solid tumors.

Lasofoxifene Suppresses Ki-67 Expression in HR+/HER2– Early-Stage Breast Cancer

November 4th 2024

Lasofoxifene was well tolerated and had early activity signals in patients with HR-positive, HER2-negative, locally advanced breast cancer.

Research Sheds Light on Gaps in Care Faced by Patients With MBD From Primary Cancers

November 2nd 2024

Secondary metastatic involvement in the musculoskeletal system due to primary cancers and MBD affect patient quality of life and create gaps in care.

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

November 1st 2024

The phase 2 study of masofaniten plus enzalutamide in mCRPC naive to second-generation antiandrogen therapy has been discontinued.

Ameluz-PDT Leads to Target Lesion Clearance in Superficial Basal Cell Carcinoma

November 1st 2024

Ameluz-PDT generated statistically significant target lesion clearance outcomes vs placebo-PDT in superficial basal cell carcinoma.

Revisit Every OncLive On Air Episode From October 2024

November 1st 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

SUNLIGHT QOL Data Show Positive Outcomes With Trifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD

October 31st 2024

Dr Hubbard discusses efficacy, safety, and quality of life outcomes from the SUNLIGHT trial of trifluridine-tipiracil plus bevacizumab in metastatic CRC.

Patient Communication is Key to Delivering Optimal PARP Inhibitor Treatment in Ovarian Cancer

October 30th 2024

Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.

Dr Braunstein on Novel Risk Factors for Veno-Occlusive Disease Development

October 30th 2024

Marc J. Braunstein, MD, PhD, discusses VOD risk factors, management strategies, and prevention strategies in the post-HSCT hematologic malignancy setting.

Dr Sborov on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

October 30th 2024

Douglas W. Sborov, MD, MS, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

NCCN Guideline Update Recommends Adjuvant Ribociclib Plus AI in HR+/HER2– Early Breast Cancer

October 29th 2024

The October 2024 NCCN Clinical Practice Guidelines in Oncology for breast cancer recommend ribociclib plus an AI in adjuvant HR+/HER2– early breast cancer.

Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD

October 28th 2024

Dr Gandara discusses the optimal use of liquid biopsy for patients with NSCLC and available treatment options for patients with KRAS-mutant NSCLC.

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Regular Toxicity Monitoring

October 28th 2024

Douglas W. Sborov, MD, MS, discusses where ide-cel and cilta-cel each fit into the myeloma treatment paradigm.